FDA approves Isentress at a higher dose for HIV-1 infected patients.
A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.
FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
A new study led by The University of California researchers and published in JAMA reveals surprising findings.
FDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.
Based on new data from 2 large clinical trials, FDA is warning that these blockbuster type 2 diabetes medications can cause an increased risk of leg and foot amputations.